Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 2, 2006, Pages 175-179

  Ozmen, Habibe ^a   Erulas, Fatih Ahmet ^a   Karatas, Fikret ^a   Cukurovali, Alaaddin ^a   Yalcin, Orhan ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Lipid peroxidation; Prostate cancer; Trace elements; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; COBALT; COPPER; IRON; MALONALDEHYDE; NICKEL; RETINOL; SELENIUM; TRACE METAL; ZINC;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; LIPID PEROXIDATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TRACE METAL BLOOD LEVEL; VITAMIN BLOOD LEVEL; ZINC BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ASCORBIC ACID; COBALT; COPPER; HUMANS; IRON; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; NICKEL; PROSTATIC NEOPLASMS; SELENIUM; TRACE ELEMENTS; VITAMIN A; VITAMIN E; ZINC;

ANIMALIA;

EID: 32544450647     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2006.032     Document Type: Article

References (40)

1. Templar J, Kon SP, Milligan TP, Newman DJ, Raftery MJ. Increased plasma malondialdehyde levels in glomerular disease as determined by a fully validated HPLC method. Nephrol Dial Transpl 1999;14:946-51.
2. Das U. A radical approach to cancer. Med Sci Monit 2002;8:79-92.
3. Halliwell B. Effect of diet on cancer development: is oxidative DNA damage a biomarker? Free Radic Biol Med 2002;15:968-74.
4. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075-107.
5. Babbs CF. Free radicals and etiology of colon cancer. Free Radic Biol Med 1990;8:191-201.
6. Moon RC, McCormick DL, Mehta RG. Inhibition of carcinogenesis by retinoids. Cancer Res 1983;43:2469-75.
7. Halliwell B. Free radical antioxidants in human disease. Curiosity, cause or consequence? Lancet 1994;344:72-4.
8. Kolonel LN, Hinds MW, Nomura AM, Hankin JH, Lee J. Relationship of dietary vitamin A and ascorbic acid intake to the risk for cancers of the lung, bladder and prostate in Hawaii. Natl Cancer Inst Monogr 1985;69:137-42.
9. Tehophanides T, Anastassopoulou J. Copper and carcinogenesis. Crit Rev Oncol Hematol 2002;42:57-64.
10. Bray TM, Better WJ. The physiological role of zinc as an antioxidant. Free Radic Biol Med 1990;8:281-91.
11. Gouget B, Sergeant C, Llabador Y, Deves G, Vesvres MH, Simonoff M. Trace metals and cancer: the case of neuroblastoma. Nucl Instrum Methods B 2001;181:465-9.
12. Desoize B. Cancer and metals and metal compounds: part I - carcinogenesis. Crit Rev Oncol Hematol 2002;42:1-3.
13. Miller KW, Lorr NA, Yang CS. Simultaneous determination of plasma retinol, α-tocopherol, lycopene, α-carotene, and β-carotene by high performance liquid chromatography. Anal Biochem 1984;138:340-5.
14. Cerhata D, Bauerova A, Ginter B. Determination of ascorbic acid in serum using high performance liquid chromatography and its correlation with spectrophotometric (colorimetric) determination. Ceska Slov Farm 1994;43:166-70.
15. Tavazzi B, Lazzarino G, Di-Piero D, Giardina B. Malondialdehyde production and ascorbate decrease are associated to the reperfusion of the isolated postischemic rat heart. Free Radic Biol Med 1992;13:75-8.
16. Karatas F, Karatepe M, Baysar A. Determination of free malondialdehyde in human serum by high performance liquid chromatography. Anal Biochem 2002;311:76-9.
17. Whetter PA, Ullrey DE. Improved fluorometric method for determining selenium. J Assoc Anal Chem 1978;61:927-30.
18. Goodman GE, Schaffer S, Omenn GS, Chen C, King I. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 2003;12:518-26.
19. Reichman ME, Hayes RB, Ziegler RG, Schatzkin A, Taylor PR, Kahle LL, et al. Serum vitamin A and subsequent development of prostate cancer in the first National Health and Nutrition Examination Survey epidemiologic follow-up study. Cancer Res 1990;50:2311-5.
20. Hayes RB, Bogdanovicz JF, Schroeder FH, De Bruijn A, Raatgever JW, Van der Maas PJ, et al. Serum retinol and prostate cancer. Cancer 1988;62:2021-6.
21. Shibata A, Paganini-Hill A, Ross RK, Henderson BE. Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. Br J Cancer 1992;66:673-9.
22. Benedict WF, Jones PA. Inhibition of transformation and oncogenic progression by ascorbic acid: a possible role in chemoprevention. In: Arnot MS, van Eys J, Wang YM, editors. Molecular interrelations of nutrition and cancer. New York: Raven Press, 1982:351-7.
23. Yalcin O, Karatas F, Erulas FA, Özdemir E. The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. BJU Int 2004;93:863-6.
24. Suhr D, Brummer F, Irmer U, Schlachter M, Hulser DF. Reduced cavitation-induced cellular damage by the antioxidative effect of vitamin E. Ultrasonics 1994;32:301-7.
25. Al-Saleh IA, Al-Doush I. Selenium levels in wheat grains grown in Saudi Arabia. Bull Environ Contam Toxicol 1997;59:590-4.
26. Willett WC, Polk BF, Morris JS, Stampfer MJ, Pressel S, Rosner B, et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983;2:130-4.
27. Barrington JW, Jones A, James D, Smith S, Stephenson TP. Antioxidant deficiency following clam enterocystoplasty. Brit J Urol 1997;80:238-42.
28. Meuillet E, Stratton S, Prasad Cherukuri D, Goulet AC, Kagey J, Porterfield B, et al. Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. J Cell Biochem 2004;91:443-58.
29. Gonenc A, Ozkan Y, Torun M, Simsek B. Plasma malondialdehyde (MDA) levels in breast and lung cancer patients. J Clin Pharm Ther 2001;26:141-4.
30. Siddiqui MK, Srivastava S, Mehrotra PK. Environmental exposure to lead as a risk for prostate cancer. Biomed Environ Sci 2002;15:298-305.
31. Biri H, Cimen MY, Kacmaz M, Buyukkocak S, Sen I, Ozturk HS, et al. Antioxidant potential of cancerous human kidney tissues. Cancer Biochem Biophys 1998;16:265-72.
32. Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 2003;95:1004-7.
33. Coates RJ, Weiss NS, Daling JR, Rettmer RL, Warnick GR. Cancer risk in relation to serum copper levels. Cancer Res 1989;49:4353-6.
34. Ma EL, Jiang ZM. Ion-exchange chromatography in simultaneous determination of serum copper and zinc levels in patients with cancer of digestive tract. Chin Med J Peking 1993;106:118-21.
35. Picurelli L, Olcina PV, Roig MD, Guntherner S, Ferrer J. Determination and relationship of the copper and zinc concentrations in normal and pathological prostatic tissue. Trace Elem Med 1991;8:131-7.
36. Picurelli L, Olcina PV, Roig MD, Guntherner S, Ferrer J. Determination and relationship of the iron and magnesium concentrations in normal and pathological prostatic tissue. Trace Elem Med 1992;9:14-9.
37. Faroon OM, Williams M, O'Connor R. A review of the carcinogenicity of chemicals most frequently found at national priorities list sites. Toxicol Ind Health 1994;10:203-30.
38. Hall IH, Lackey CB, Kistler TD, Durham RW Jr, Russell JM, Grimes RN. Antitumor activity of mono- and dimetallic transition metal carborane complexes of Ta, Fe, Co, Mo, or W. Anticancer Res 2000;20:2345-54.
39. Mitchell CR, Folkard M, Joiner MC. Effects of exposure to low-dose-rate (60)Co gamma rays on human tumor cells in vitro. Radiat Res 2002;158:311-8.
40. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005;12:1161-208.